The Houston Consensus Conference on Testing for Helicobacter pylori Infection

Josephson, Matthew; Skole, Kevin

doi:10.1016/j.cgh.2018.08.018

Cited by 5 publications

(4 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32,53 The variability seen in how PgII levels respond to the eradication effort may plausibly have to do with the fact that the efficacy of the treatment in downmodulating or clearing the inflammatory lesions (and lowering PgII levels as a consequence) may not necessarily reflect a successful eradication of the infection. [54][55][56] On the other hand, the successful eradication of H. pylori may not always be associated with patients' inflammatory lesions disappearing (and their serum PgII levels dropping). [57][58][59][60][61] One limitation of the study is due to the fact that in the majority of the studies included in the review, the PGII role and properties were not intended as primary aims.…”

Section: F I G U R E 1 Flow Chart Of Literature Search and Selectionmentioning

confidence: 99%

Pepsinogen II in gastritis and Helicobacter pylori infection

et al. 2022

View full text Add to dashboard Cite

Background and Aim In the gastric mucosa, pepsinogen II (PgII) is produced/secreted by glands in the mucus‐secreting antral and cardia compartments, but also by the chief cells and the oxyntic glands. Increasing PgII serum levels are associated with the whole spectrum of gastric inflammatory diseases, including gastritis induced by Helicobacter pylori (H. pylori). This review critically addresses the clinical value of PgII serology for assessing gastric mucosal inflammation, and as a marker of H. pylori status, in both H. pylori‐positive patients and after eradication therapy. Results A search in PubMed/Scopus records yielded 39 out of 1190 published scientific studies meeting the selection criteria for this study. In the studies considered, PgII levels were significantly associated with non‐atrophic gastric inflammatory lesions (p‐values: 0.025–0.0001). H. pylori‐positive patients had significantly higher PgII levels than H. pylori‐negative individuals (p‐values: 0.o5–0.0001). While a significant drop in serum PgII levels is consistently reported in H. pylori‐eradicated patients (p‐values: from 0.05 to 0.0001), inconsistencies in the related negative and positive predictive values significantly lower the clinical reliability of PgII testing by comparison with other available non‐invasive tests. Conclusions PgII serology may provide clinically useful information on gastric inflammatory diseases, particularly if they are non‐atrophic. PgII serology is inconsistent, however, for the purposes of distinguishing patients whose H. pylori eradication therapy is successful from those who remain infected.

show abstract

Section: F I G U R E 1 Flow Chart Of Literature Search and Selectionmentioning

confidence: 99%

Pepsinogen II in gastritis and Helicobacter pylori infection

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Gastric cancer is thought to be frequently caused by chronic H. pylori infection (Fallone et al, 2016). Around the world, more than 89% of gastric cancer cases are found to be related to H. pylori infection (Josephson and Skole, 2018;Turabi et al, 2022). In 1994, the WHO International Agency for Research on Cancer (IARC) confirmed H. pylori as a Group I carcinogen and its eradication is very important to prevent gastric cancer among both developed and developing nations (Hooi et al, 2017;Chatterjee et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Stable expression ofHelicobacter pylori cagAoncoprotein in brinjal

Mehran,

Barzigar,

Sathish Kumar

et al. 2023

Preprint

View full text Add to dashboard Cite

Helicobacter pylori is closely connected to upper gastrointestinal tract diseases including gastric cancer. Transgenic plants are found to be successful in expressing the bacterial antigens, which could elicit an immune response when consumed. The Cytotoxicity-associated immunodominant antigen protein (cagA) of H. pylori is kindred with pathogenicity and cancer risk. We expressed the cagA transgenically in the brinjal. We amplified the cagA gene from H. pylori strain 26695 chromosomal DNA and transformed it into brinjal callus derived from leaf explants using the pBI121 expression vector. The stable expression and accumulation of the recombinant cagA gene were confirmed by using quantitative real-time PCR, western blot analysis and ELISA. The RT-PCR, western blot and ELISA showed stable expression of cagA gene in the transgenic lines B3, B5, B11, B17 and B21. Among them, B11 and B17 samples showed higher expression of the cagA compared to the other samples. Besides, the immunohistochemistry assay showed the abundant expression of cagA protein in the parenchymal regions of the transgenic plants. Out of the 52 plants, a set five plants were found to be positive for cagA expression. Our experimental outcomes can be used further to design the vaccines against H. pylori from the transgenic brinjal plants.

show abstract

“…In 2015, the Kyoto global consensus report on H. pylori gastritis recommended that all H. pylori -infected individuals should be offered eradication therapy unless there are competing considerations 8. This recommendation was subsequently adopted in other updated guidelines or expert consensuses for the management of H. pylori infection 9–13. However, large-scale treatment of H. pylori in the general population is not feasible.…”

Section: Introductionmentioning

confidence: 99%

“…8 This recommendation was subsequently adopted in other updated guidelines or expert consensuses for the management of H. pylori infection. [9][10][11][12][13] However, large-scale treatment of H. pylori in the general population is not feasible. First, more than half the global population is infected with H. pylori, making the cost for therapy immeasurable.…”

mentioning

confidence: 99%

School-based Hygiene Intervention to PreventHelicObacter Pyloriinfection among childrEn (SHIP HOPE): protocol for a cluster-randomised controlled trial

Zhou

Zeng

et al. 2022

BMJ Open

View full text Add to dashboard Cite

IntroductionHelicobacter pyloriinfection rates are high in China and worldwide, and maintaining good hygiene is effective in preventingH. pyloriinfection. Childhood is a critical stage for developing good hygiene practices. Therefore, in this study, we aimed to explore whether a comprehensive hygiene intervention can preventH. pyloriinfection in primary schools in China.Methods and analysisThe School-based Hygiene Intervention to PreventHelicObacter Pyloriinfection among childrEn study is a cluster-randomised controlled trial, which will include approximately 2400 children in grades 2–4 from 60 classes in 10 primary schools of Linqu County, Shandong Province. Schools will be randomly assigned (1:1) via a computer-generated list, to receive either comprehensive hygiene intervention (intervention) or the usual health education lessons (control), with stratification by area (urban or rural). The interventions will include the following: (1) Children’s education: lessons and cartoon books designed to provide basic knowledge about hygiene,H. pylori, hand hygiene, diet and oral hygiene will be provided to children; (2) Caregiver’s education: children will be empowered to share hygiene-related knowledge with their caregivers as homework; caregivers will be also invited to the school for hygiene lessons; (3) School hygiene promotion: suggestions will be provided for improving the hygienic environment. Children in control schools will receive usual health education lessons according to the arrangements of each school. The primary outcome is the prevalence and incidence ofH. pyloriinfection among children at 1-year follow-up. The secondary outcomes areH. pyloriand hygiene knowledge, family eating customs and hygiene practices among children and their caregivers, as well as school absences owing to diarrhoea. Additionally, growth in children is set as an exploratory outcome. General linear mixed models will be used to analyse differences between the intervention and control schools.Ethics and disseminationEthics approval has been obtained from the Institution Review Board of Tsinghua University (No: 20220020). Written informed consent will be obtained from each child and one of their caregivers. The findings of this study will be actively disseminated through scientific publications and conference presentations.Trial registration numberChiCTR2200056191.

show abstract

The Houston Consensus Conference on Testing for Helicobacter pylori Infection

Cited by 5 publications

References 4 publications

Pepsinogen II in gastritis and Helicobacter pylori infection

Pepsinogen II in gastritis and Helicobacter pylori infection

Stable expression ofHelicobacter pylori cagAoncoprotein in brinjal

School-based Hygiene Intervention to PreventHelicObacter Pyloriinfection among childrEn (SHIP HOPE): protocol for a cluster-randomised controlled trial

Contact Info

Product

Resources

About